Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial

E. Felip,N. Altorki,C. Zhou,E. Vallières,A. Martínez-Martí,A. Rittmeyer,A. Chella,M. Reck,O. Goloborodko,M. Huang,R. Belleli,V. McNally,M.K. Srivastava,E. Bennett,B.J. Gitlitz,H.A. Wakelee

Annals of Oncology（2023）

Cited 3|Views6

No score

Abstract

•Atezolizumab significantly improved DFS versus BSC after resection and adjuvant chemo in PD-L1+ stage II-IIIA NSCLC.•Atezolizumab appears to extend OS versus BSC post resection and adjuvant chemo in PD-L1 TC ≥50% stage II-IIIA NSCLC.•Although OS was immature, a positive trend favouring atezolizumab that was greatest in the PD-L1 TC ≥50% stage II-IIIA group.

Translated text

Key words

adjuvant atezolizumab,chemotherapy,lung cancer,ii-iiia,non-small-cell,open-label

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined